+Compare
LIAN
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
268.98M

LIAN LianBio Forecast, Technical & Fundamental Analysis

Industry Biotechnology
GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT May 26, 2023

LIAN's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for LIAN moved out of overbought territory on May 22, 2023. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 instances where the indicator moved out of the overbought zone. In of the 9 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 14 cases where LIAN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIAN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LIAN broke above its upper Bollinger Band on May 17, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 16, 2023. You may want to consider a long position or call options on LIAN as a result. In of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LIAN just turned positive on May 17, 2023. Looking at past instances where LIAN's MACD turned positive, the stock continued to rise in of 11 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for LIAN moved above the 200-day moving average on May 18, 2023. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where LIAN advanced for three days, in of 74 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 31 cases where LIAN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.118) is normal, around the industry mean (24.635). P/E Ratio (1.552) is within average values for comparable stocks, (122.909). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.359). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (302.885).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LIAN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.13B. The market cap for tickers in the group ranges from 365 to 363.75B. NONOF holds the highest valuation in this group at 363.75B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 51%, and the average quarterly price growth was 54%. LABP experienced the highest price growth at 871%, while RAIN experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -32%. For the same stocks of the Industry, the average monthly volume growth was -34% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 50
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

LIAN is expected to report earnings to rise 43.18% to -31 cents per share on August 10

LianBio LIAN Stock Earnings Reports
Q2'23
Est.
$-0.31
Q1'23
Beat
by $0.07
Q4'22
Beat
by $0.10
Q3'22
Beat
by $0.19
Q2'22
Missed
by $0.11
The last earnings report on May 12 showed earnings per share of -21 cents, beating the estimate of -28 cents. With 116.63K shares outstanding, the current market capitalization sits at 268.98M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
103 Carnegie Center Drive
Phone
+1 609 486-2308
Employees
163
Web
https://www.lianbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SNIEX20.82N/A
N/A
BNY Mellon International Equity I
PRETX23.65N/A
N/A
Principal Real Estate Securities R4
PSBJX21.20N/A
N/A
Principal SmallCap J
ARLSX9.61N/A
N/A
AMG River Road International Value Eq N
PZIMX12.54N/A
N/A
Pzena Mid Cap Value Instl

LIAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LIAN has been loosely correlated with FATE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if LIAN jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIAN
1D Price
Change %
LIAN100%
-2.79%
FATE - LIAN
47%
Loosely correlated
+1.79%
CERE - LIAN
40%
Loosely correlated
+2.55%
CRSP - LIAN
39%
Loosely correlated
+1.27%
BEAM - LIAN
39%
Loosely correlated
+0.50%
DNA - LIAN
39%
Loosely correlated
-1.63%
More